Area Coordinators: Yvonne Chen, Yonghyun (John) Kim, John Pieracci
Name: Shreyas Rao
Affiliation: The University of Alabama
Name: Pani Apostolidis
Affiliation: Bristol Myers Squibb
A substantial amount of effort in biotechnology research is focused on improving methods to culture, expand, and utilize various types of stem cells for numerous in vitro and in vivo applications, including the engineering of tissues and the delivery or directing of stem cells for therapeutic, regenerative medicine and disease modeling applications. This session will focus on new enabling technologies for stem cell and tissue engineering. Topics will include, but are not limited to i) engineered biomaterials to promote the growth, patterning, and three dimensional culture of stem cells or tissue engineering constructs, ii) novel technologies to de novo engineer tissues, organs or bioreactor systems to provide controllable and reproducible culture environments, iii) biomimetic culture systems to study stem cell biology and iv) applications to expand and differentiate cells along tissue specific lineages, novel biomimetic platforms (e.g., chip based) for drug screening, transplantation methods, in vitro disease models, and new therapeutic applications of stem cells and engineered tissues.
Name: Yvonne Chen
Affiliation: University of California, Los Angeles
Name: Eric Gschweng
Affiliation: Kite Pharma
This session will focus on emerging technologies in the context of cell-based immunotherapy, including but not limited to the use of cytotoxic T cells, regulatory T cells, natural killer cells, and other immune cell types against cancer, viral infections, as well as autoimmune and inflammatory diseases. Advancements in hematopoietic cell transplant and other areas of cell-based immunotherapy are also encouraged. Relevant topics include protein design, genome editing, cell manufacturing, and clinical deployment as related to cell-based immunotherapeutics.
Name: John Pieracci
Affiliation: Biogen Corporation
Name: Chase Beisel
Affiliation: North Carolina State University
Gene therapy has the potential to radically change the current approach to treating human diseases by rewriting our own genetic material. The field has existed for decades, yet recent advances in genomics, gene editing technologies, and delivery vehicles have spurred a resurgence in fundamental research and clinical trials. This session will focus on a wide range of aspects of gene therapy and gene editing. These include: i) genomics tools and approaches for elucidating and validating gene editing
targets, ii) the development and application of genome editing tools such as zinc fingered endonucleases (ZFNs), transcription activator like effector based nucleases (TALENs), and CRISPR Cas9, iii) engineering delivery vehicles to specifically target tissues and cell types and efficiently deliver the genome editing cargo, and iv) the safe and scalable production of viral vectors (e.g. lentiviral and adenoviral) and other delivery vehicles.
Name: Zengyi Shao
Affiliation: Iowa State University
Name: Hannah Victor
This session will focus on emerging technologies used for the engineering of cells and their interaction in the context of a community for various biotechnological applications. Talks are welcome on a broad range of topics including, but not limited to, host cell engineering or modification to improve protein production, genetic stability, post-translational modification including glycosylation, cellular reprogramming, genetic circuit design, signal transduction, cell-cell communication, host-pathogen interaction and evolution. Of particular interest are efforts in studying and designing microbiome to realize complex and sophisticated cellular functions and provide extra gains in design efficiency and execution of bioengineering solutions.
Name: Benjamin Hackel
Affiliation: University of Minnesota
Name: David Liu
Name: Chris Pirie
Precision medicine uses disease-specific molecular information to provide higher response rates and more specific, targeted activity. This session will focus on technologies and fundamental studies that advance our capabilities and understanding of precision medicine including, but not limited to, molecular imaging, anatomical imaging, ex vivo diagnostics, biomarker discovery, molecular targeting agents, and molecularly targeted therapies. Experimental, theoretical, and combined studies at all stages of development are welcome.
Name: Sadettin S Ozturk
Name: Leonardo Morsut
Affiliation: University of California, San Francisco
Many emerging new tools and approaches at the molecular level possess the potential to generate significant impact on human health and the understanding of biological systems. These new tools are enabling the development of the next generation emerging technologies of biotherapeutics, diagnostic, basic research: from improving the controls on cellular behavior with synthetic biology approaches, to the generation of increasingly powerful and smart biologics. This session is broadly open to new molecular and biochemical tools with application to basic biology and biotechnology. Talks are welcome on topics pertaining protein and pathway engineering (synthetic antibodies, synthetic receptors, synthetic transcription factors, biosensors), as well as to the applications of gene editing tools and the utilization of genomics and transcriptomics for the development of high producing cell lines and for the optimization of product quality in the area of process and product development.